Research To Practice | Oncology Videos

Latest Episodes:

Non-Hodgkin Lymphoma | Matthew Matasar, MD Aug 25, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Novel Treatment Approaches for Non-Hodgkin Lymphoma | Faculty Presentation 1: Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Matthew Matasar, MD

CME information and select publications

HR-Positive Metastatic Breast Cancer — Year in Review Series on Relevant New Datasets and Advances in the PI3K/AKT/mTOR Pathway Aug 24, 2026

Show notes

Featuring perspectives from Dr Virginia Kaklamani and Dr Hope S Rugo, including the following topics:

Introduction: San Antonio Memories (0:00)
PI3K/AKT/PTEN Alterations and Therapies (7:18)
Capivasertib (20:22)
Gedatolisib (34:08)
Inavolisib (47:07)
New Agents and Ongoing Trials (52:34)

CME information and select publications

For Oncology Nurses: Pancreatic Cancer — Proceedings from the 2026 Annual ONS Congress Aug 24, 2026

Show notes

Featuring perspectives from Ms Caroline Kuhlman, Dr Eileen M O'Reilly, Dr Philip A Philip and Ms Amanda K Wagner, moderated by Dr O'Reilly, including the following topics:

· Introduction (0:00)

· Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD) (3:29)

· Recent Advances in Up-Front Treatment for Metastatic PAD (15:47)

· Selection and Sequencing of Therapy for Relapsed/Refractory Metastatic PAD (39:58)

· Novel Strategies Targeting RAS Mutations in Advanced PAD (48:20)

· Utility of Tumor Treating Fields in PAD Management (1:13:58)

CME information and select publications

Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Hope S Rugo, MD Aug 23, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances Involving the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Faculty Presentation 2: Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive mBC — Hope S Rugo, MD

CME information and select publications

Targeting the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Virginia Kaklamani, MD, DSc Aug 23, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances Involving the PI3K/AKT/mTOR Pathway in HR-Positive Metastatic Breast Cancer | Faculty Presentation 1: Identification of Appropriate Candidates with HR-Positive Metastatic Breast Cancer (mBC) for Agents Targeting the PI3K/AKT/mTOR Pathway; Role in the Up-Front Setting — Virginia Kaklamani, MD, DSc

CME information and select publications

AKT Inhibition in Prostate Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium Aug 22, 2026

Show notes

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

Treatment approach for AKT-mutated prostate cancer — Question from Neeraj Agarwal, MD, FASCO (0:00)
Case: A man in his late 60s with de novo metastatic hormone-sensitive prostate cancer with widespread skeletal metastases and PTEN loss on next-generation sequencing receives relugolix/darolutamide with chemotherapy and experiences PSA decline that plateaus at approximately 1 ng/mL — Rana R McKay, MD, FASCO (10:29)

CME information and select publications

AKT Inhibition in Prostate Cancer — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium Aug 21, 2026

Show notes

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:

Role of PTEN deficiency in tumorigenesis of prostate cancer and optimal approach to PTEN assessment — Question from Neeraj Agarwal, MD, FASCO (0:00)
Case: A man in his late 60s with a history of nonmetastatic hormone-sensitive prostate cancer (HSPC) that progressed to metastatic HSPC with PTEN loss by next-generation sequencing of primary archival tissue from 2017 receives abiraterone for 2 years — Rana R McKay, MD, FASCO (8:26)

CME information and select publications

Gastroesophageal Cancers — Year in Review Series on Relevant New Datasets and Advances Aug 20, 2026

Show notes

Featuring perspectives from Dr David H Ilson and Dr Kohei Shitara, including the following topics:

Introduction (0:00)
Biomarker Evaluation in Localized and Metastatic Disease (1:49)
Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — Dr Ilson (7:37)
Other Available Therapeutic Approaches — Dr Shitara (33:22)

CME information and select publications

Gastroesophageal Cancers | David H Ilson, MD, PhD Aug 19, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gastroesophageal Cancers | Faculty Presentation 1: Role of Immune Checkpoint Inhibitors in the Management of Gastroesophageal Cancers — David H Ilson, MD, PhD

CME information and select publications

Gastroesophageal Cancers | Kohei Shitara, MD Aug 19, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gastroesophageal Cancers | Faculty Presentation 2: Other Available Therapeutic Approaches — Kohei Shitara, MD

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected